• Citer

Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.

par Schröder, Fritz;Whelan, Peter;De Reijke, Theo M.;Kurth, Karlheinz;Pavone-Macaluso, Michele;Mattelaer, J;Van Velthoven, Roland ;Debois, Muriel;Collette, Laurence;Members of the EORTC Genito-Urinary Group,
Référence European urology, 45, 4, page (457-464)
Publication Publié, 2004-04

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
Auteur:	Schröder, Fritz; Whelan, Peter; De Reijke, Theo M.; Kurth, Karlheinz; Pavone-Macaluso, Michele; Mattelaer, J; Van Velthoven, Roland; Debois, Muriel; Collette, Laurence; Members of the EORTC Genito-Urinary Group,
Informations sur la publication:	European urology, 45, 4, page (457-464)
Statut de publication:	Publié, 2004-04
Sujet CREF:	Cancérologie
MeSH keywords:	Aged
	Aged, 80 and over
	Androgen Antagonists -- therapeutic use
	Cyproterone Acetate -- therapeutic use
	Disease Progression
	Flutamide -- therapeutic use
	Humans
	Male
	Middle Aged
	Neoplasm Metastasis
	Prostatic Neoplasms -- drug therapy -- pathology
	Survival Rate
Note générale:	Clinical Trial
	Comparative Study
	Journal Article
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
	Research Support, U.S. Gov't, P.H.S.
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0302-2838
	info:doi/10.1016/j.eururo.2003.11.016
	info:pii/S0302283803005918
	info:scp/17144459258
	info:pmid/15041109